BDX · XBRL financial data

Becton, Dickinson and Company financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BDX's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue	17,117	20,248	18,870	19,372	20,178	21,840
Cost of goods and services sold	9,540	10,821	10,393	11,202	11,053	11,915
Gross profit	7,577	—	—	—	—	—
Research and development	1,096	1,339	1,256	1,237	1,190	1,265
Selling, general and administrative	4,325	4,867	4,709	4,719	4,857	5,278
Other operating income (expense)	(363)	(238)	(37)	210	(222)	(396)
Operating income (loss)	1,484	2,799	2,282	2,111	2,397	2,579
Interest income	7	9	16	49	163	38
Interest expense	528	469	398	452	528	613
Other income (expense)	23	(97)	(117)	(46)	(28)	(123)
Income tax expense (benefit)	111	150	148	132	300	203
Net income (loss)	874	2,092	1,779	1,484	1,705	1,678
Earnings per share, basic USD per share	2.75	6.92	5.93	4.97	5.88	5.83
Earnings per share, diluted USD per share	2.71	6.85	5.88	4.94	5.86	5.82
Weighted average shares, basic millions of shares	279	289	285	286	290	288
Weighted average shares, diluted millions of shares	282	292	287	288	291	289

Fiscal years (BDX's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	2,825	2,283	1,006	1,416	1,717	641
Accounts receivable	2,398	2,497	2,191	2,534	3,033	2,994
Inventory	2,743	2,866	3,224	3,273	3,843	3,894
Total current assets	8,969	8,838	8,141	8,676	10,468	9,255
Property and equipment, net	5,923	6,393	6,012	6,557	6,821	6,997
Right-of-use asset	418	446	482	517	876	885
Goodwill	23,620	23,901	24,621	24,522	26,465	26,612
Total assets	54,012	53,866	52,934	52,780	57,286	55,325
Accounts payable	1,355	1,793	1,699	1,641	1,896	1,974
Accrued liabilities	2,638	2,943	2,605	2,604	3,476	3,103
Total current liabilities	5,836	6,626	7,811	6,641	8,956	8,313
Long-term debt	17,224	17,110	13,886	14,738	17,940	17,621
Lease liability, non-current	336	344	384	414	667	704
Retained earnings	12,791	13,826	15,157	15,535	16,139	16,622
Total stockholders' equity	23,765	23,677	25,282	25,796	25,890	25,390
Total liabilities and equity	54,012	53,866	52,934	52,780	57,286	55,325
Common shares outstanding (cover page) millions of shares	290	284	283	290	289	285

Fiscal years (BDX's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	874	2,092	1,779	1,484	1,705	1,678
Stock-based compensation	244	237	233	259	247	258
Depreciation and amortization	2,154	2,273	2,229	2,288	2,286	2,462
Net cash from operating activities	3,539	4,647	—	—	—	—
Purchases of property and equipment	810	1,231	973	874	725	760
Net cash from investing activities	(1,232)	(1,880)	—	(716)	(5,514)	(818)
Proceeds from issuing equity	2,917	0	0	—	—	—
Share repurchases	0	1,750	500	0	500	1,000
Dividends paid	1,026	1,048	1,082	1,114	1,100	1,196
Proceeds from long-term debt	3,389	4,869	497	1,662	4,517	0
Repayments of long-term debt	4,664	5,112	805	2,155	1,142	1,789
Net cash from financing activities	22	(3,306)	—	(1,956)	2,087	(3,617)
Net change in cash	2,326	(525)	(1,233)	322	375	(1,005)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Becton Dickinson	708	4,983	not reported	272.4M	Q3 FY26 10-QJun 30, 2026
3M	4,835	6,584	486*	516.7M	Q3 FY26 10-QSep 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	Q2 FY26 10-QJun 30, 2026
Medtronic	1,691	9,756	1,793	1.3B	Q1 FY27 10-QJul 31, 2026
Resmed	1,011	1,415	422	140.7M	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	Q3 FY26 10-QSep 30, 2026
Stryker	3,271	6,520	1,461*	380.7M	Q3 FY26 10-QSep 30, 2026
Boston Scientific	609	5,138	1,048*	1.4B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.